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REKA CIPTA, SINTESIS DAN PENCIRIAN ANALOG ASID 4-
OKSOBUTANOIK YANG BERPOTENSI SEBAGAI PERENCAT FAKTOR 





 Terdapat penyedaran minat dalam mengembang perencat faktor pendorong 
hipoksia manusia (HIF) prolil hidroksilasi bagi merawat penyakit iskemik/hipoksik. 
Dalam kajian ini, satu siri baru analog asid 4-Oksobutanoik yang berpotensi telah 
diselidik sebagai perencat HIF prolil hidroksilasi 2 (PHD-2). Sebatian tersebut direka 
berdasarkan kebolehan perencat mengikat secara bidentat pada tapak aktif PHD-2, dari 
segi bentuk pengikatan yang paling sesuai dengan menggunakan Autodock 4.0 dan 
Accelrys Discovery Studio 4.0. Analog asid 4-Oksobutanoik telah disintesiskan 
menggunakan amina dan sulfonamida bersama suksinik anhidrida. Sebatian yang telah 
disintesis lalu dicirikan menggunakan 1D-NMR (1H, 13C), 2D-NMR (COSY, HSQC dan 
HMBC), FTIR, analisis unsur CHN dan DIMS. Sistem cerakin RapidFire PHD-2 
digunakan sebagai kajian lanjutan untuk mengenal pasti potensi perencatan analog asid 
4-Oksobutanoik terhadap PHD-2. Hasil cerakin RapidFire PHD-2 in vitro menunjukkan 
bahawa sebatian F2a dan F2b ialah perencat berpotensi, dengan nilai IC50 masing-masing 
242 nM dan 160 nM, diikuti dengan F3a dengan nilai IC50 71.2 μM. F2a dan F2b didapati 
lebih berpotensi dalam merencatkan PHD-2 daripada calon kawalan positif FibroGen 
FG4592 yang kini sedang menjalani fasa ketiga klinikal dalam merawat anemia pada 






DESIGN, SYNTHESIS AND CHARACTERIZATION OF 4-OXOBUTANOIC 
ACID ANALOGUES AS POTENTIAL HUMAN HYPOXIA INDUCIBLE 




There is a widespread interest in developing the human hypoxia inducible factor 
(HIF) prolyl hydroxylase inhibitors for the treatment of ischemic/hypoxic diseases. In this 
study, a new series of 4-oxobutanoic acid analogues was investigated as potential HIF 
prolyl hydroxylase domain-2 (PHD-2) inhibitors. The compounds were designed based 
on their binding capabilities to the PHD-2 active sites in a bidentate manner, with the 
most favorable binding modes in the molecular docking studies using Autodock 4.0 and 
Accelrys Discovery Studio 4.0. The compounds were synthesized by reacting amines and 
sulfonamides with succinic anhydride. The synthesized compounds were further 
characterized using 1D-NMR (1H, 13C), 2D-NMR (COSY, HSQC and HMBC), FTIR, 
CHN elemental analysis and DIMS. PHD-2 RapidFire assay was further employed to 
determine the in vitro inhibitory potencies of the 4-oxobutanoic acid analogues against 
PHD-2. The assay results revealed that compounds F2a and F2b were potent PHD-2 
inhibitors, with IC50 values of 242 nM and 160 nM, respectively followed by F3a with 
IC50 value of 71.2μM. F2a and F2b were found to be more potent in inhibiting PHD-2 
than the positive control in the assay, FibroGen’s candidate FG-4592 which is undergoing 







INTRODUCTION AND LITERATURE REVIEW 
 
1.1  Hypoxia 
Hypoxia is defined as the failure of oxygenation at the tissue level (Samuel & 
Franklin, 2008). Oxygen homeostasis is a fundamental yet crucial process for all 
organisms to survive. Upon the commencement of hypoxic conditions, cells and tissues 
trigger several adaptive responses to stabilize the energy consumption by increasing the 
ventilation, cardiac output, vascularization, oxygen transport capacity in haemoglobin 
as well as switching mode of metabolism, from aerobic into anaerobic. Prolong exposure 
to low oxygen conditions lead to the mediation of up-regulated genes encoding key actor 
for dopamine synthesis, anaerobic glycolysis, angiogenesis elicitation, erythrocyte 
proliferation and neuro protection. These responses are all mediated by the action of 
hypoxia inducible factor (HIF) (Hirota et al., 2006; Semenza, 2000). 
 
1.2  Hypoxia Inducible Factor (HIF)  
In the early 90s, an important finding from Semenza who purified hypoxia 
inducible factor (HIF) and subsequently continued with Wang (1992) using a DNA 
affinity column comprised of the cis-acting element (5’[A/G]CGTG-3’), generally 
known as hypoxia response element (HRE) proved the important role of HIF in 





oxygen needing conditions which is detrimental to mammalian cells. Hence, HIF was 
indubitably given the appellation “master of regulator”.  
HIF is a heterodimeric transcription factor that comprises of a constitutively 
expressed oxygen resistant β-subunit (HIF-β) and hypoxia regulated oxygen-labile α-
subunit (HIF-1α, HIF-2α and HIF-3α) (Ema et al., 1997; Flamme et al., 1997; Tian et 
al., 1997). Both subunits pertaining to basic helix-loops-helix (bHLH), PER-ARNT-SIM 
(PAS) superfamily of transcription factors. The bHLH consist of two highly 
distinguishing and conserved domain, basic (b) and HLH region. The basic region play 
a role in the binding of transcription factor to DNA while HLH region aid protein-protein 
interactions. The PAS domains (PAS A and PAS B) that consist of 200-350 amino acids 






Figure 1.1: Schematic sketching of HIF isoform: (a) HIF-1α. (b) HIF-1β. Abbreviations 
for N-TADN and C-TAD: Amino-terminal and carboxy-terminal transactivating 
domains; b-HLH: Basic helix loop-helix for DNA binding; PAS A and Pas B: Protein 
domain critical for dimerization. At the end of structure, the total number of amino acids 
for each subunit was labelled. (Figure reviewed from Hellwig-Bürgel, 2009; Ke and 
Costa, 2006; Semenza et al.,1998) 
 
 
Among the isoforms, HIF-1 was studied most comprehensively and close up to 
scrutiny. The HIF-1α and HIF-1β subunits are shown in Figure 1.1. In mRNA levels, 
both HIF-1α and HIF-1β, expressed constantly regardless of the partial pressure of 
oxygen due to the presence of an internal ribosome entry site (IRES) in their 
corresponding mRNA which consequently leads to the cap-independent translation of 











dependent on the oxygen tension but not HIF-1β especially in protein levels. Despite 
oxygen level depreciates below the normal range, HIF-1β subunit expression is not 
affected by the fluctuation of cellular oxygen levels and yet still able to express at 
constant level. HIF-1α is the most ubiquitously expressed α subunit in metazoans and 
have more expression patterns compared to HIF-2α and HIF-3α.  
 
1.3  Hypoxia Signaling Pathway 
HIF-1 activation begin with the stabilization and storing up of HIF-1α. 
Appropriate redox conditions and post-translational modifications such as hydroxylation, 
ubiquitination, acetylation and phosphorylation contributed to the completion of full 
transcriptional activity (Brahimi-Horn et al., 2002; Huang and Bunn, 2003; Minet et al., 
2001). HIF does not respond directly to the cellular oxygen levels as mentioned by Yan 
et al., (2010). Instead, HIF prolyl hydroxylase domain (PHD) enzymes played the role 
and catalyze the HIF prolyl hydroxylation. There are three isoforms of PHD enzymes, 
namely prolyl hydroxylase-1 (PHD-1), prolyl hydroxylase-2 (PHD-2) and prolyl 
Hydroxylase-3 (PHD-3). On the other hand, factor inhibiting HIF (FIH) is a negative 
regulator of HIF-α, catalyzed the HIF asparaginyl hydroxylation. Both PHDs and FIH 
are 2-OG/Fe2+ dependent dioxygenases which utilize oxygen as co-substrate for 













Figure 1.2: HIF prolyl hydroxylases (PHDs) and Factor inhibiting HIF (FIH) utilizing 
ferrous ion (Fe2+), 2-oxoglutarate (2-OG) and oxygen (O2) as cofactor/co-substrate to 
catalyze hydroxylation, forming hydroxy-proline/asparagine residue, succinate and 
carbon dioxide (Epstein et al., 2001; McDonough et al., 2006). 




Figure 1.3: The HIF transcriptional pathway: oxygen sensing and signaling under 



















Figure 1.3 illustrates the HIF transcriptional pathway under hypoxic and 
normoxic conditions by PHD and FIH. PHDs and FIH are extremely important in 
mediated the hypoxia signaling pathway. Under normoxic condition, two conserved 
proline residues in HIF-1α undergoes prolyl hydroxylation within the oxygen-
degradation domain (ODD): Pro402 in the N-terminal oxygen-dependent degradation 
domain (NODD) and Pro564 in the C-terminal oxygen dependent degradation domain 
(CODD), catalyzed by the PHDs in the presence of ferrous ion (Fe2+) and 2-oxoglutatrate 
(2-OG). This in turn recruits the tumor suppressor protein von Hippel-Lindau (pVHL), 
a substrate-recognition subunit of an E3 ubiquitin ligase complex to bind and activate 
the proteolysis of HIF-1α. The average half-life of HIF-1α is extremely short (< 5 minute) 
and rapidly degraded through ubiquitin-proteasome pathway (Huang et al., 1996).  At 
the same time, β-hydroxylation of conserved asparagine residue (Asn803) by FIH within 
the C-terminal transcriptional activation domain (C-TAD) restrains the uptake of co-
activator proteins p300/CBP, rendering the inactivation of HIF transcriptional activity 
(Hirota and Semenza, 2005).  
However, when cellular oxygen consumption surpasses oxygen supply, PHD-
activity is significantly reduced and the hydroxylation of HIF-1α subunits is restricted. 
This in turn results in the stabilization and accumulation of HIF-1α. This is in accordance 
to the statement from Huang et al., (1998) that HIF-1α is only detectable under hypoxic 
condition. Hypoxic conditions elevate the half-life of HIF-1α and subsequently 
translocated it into nucleus in order to dimerize with HIF-1β to form functionally 
heterodimers HIF-1 (HIF1α/HIF1β). HIF-1 binds to HREs to induce the gene 
transcription. At the same time, the co-activator complex p300/CBP being recruited and 
binds to the C-TAD region which promote the transcription of hypoxia-inducible genes. 





1.4  Prolyl Hydroxylase Domain (PHDs) 
Three independent genes have been identified coded on the human PHDs, 
namely PHD-1, PHD-2 and PHD-3. Human PHDs consist of two structural domains:  
highly conserved catalytic C-terminal, and N-terminal which is more divergent with 
limited characterization. PHDs are soluble proteins and possess about 55% similarity at 
the catalytic C-terminal (Epstein et al., 2001). PHDs are well known as an effective 
oxygen sensor due to their characteristics: first, its high Km values (≈ 240 μM) which 
are slightly higher than the atmospheric dissolved oxygen (≈ 200 μM) and second, their 
slow reaction rates with oxygen. The high Km values of the PHDs providing a sensitive 
assay to detect the fluctuation of oxygen tensions (Ehrishman et al., 2007; Hirsilä et al., 
2003). 
PHD-1 is predominantly found in nucleus with 409 amino acid residues (Metzen 
et al., 2003). It is highly expressed in testis followed by liver, heart, brain and kidney. 
However, a PHD-1 knockout study shows that the shortage of PHD-1 did not bring much 
influence on male fertility. Instead, PHD-2 which is recognized as the most abundant 
isoform, may have functions overlap with PHD-1 in playing the role in maintaining the 
reproductive capability in testis (Lieb et al., 2002). According to Cioffi et al., (2003), 
PHD-1 is induced by estrogen for cell proliferation due its nature of non-responsive to 
hypoxia in mRNA levels. 
PHD-2 is primarily present in cytoplasm, and sometimes in the nucleus. (Metzen 
et al., 2003; Soilleux et al., 2005; Steinhoff et al., 2009). It is also the longest isoform 
among the human PHDs with 426 amino acids residues, found most abundance in heart 
and testis (Lieb et al, 2002). PHD-2 is specifically induced by HIF-1α and it is crucial 
in sensing oxygen levels in the HIF degradation pathway. Appelhoff et al., (2004) 





conditions. A human PHD-2 allele mutational study by Percy et al., (2006) shows that 
reduction of PHD-2 activity is able to increase erythropoietin (EPO) production. In the 
following years, Takade and colleagues (2007) carried out a PHD-2/PHD-3 mutation 
study in liver, found that PHD-2 is significantly bias to the stabilization of HIF-1α 
instead of HIF-2α, while PHD-3 is vice versa. The study also reported that PHD-2 is the 
key isoform in adult vascular system. 
PHD-3 was found in both nucleus and cytoplasm with 239 amino acid residues, 
and highly predominates in heart (Metzen et al., 2003). PHD-3 possess significant 
impact on HIF system. It has been reported that PHD-3 is able to prolong the half-life 
of HIF-α subunits during re-oxygenation and keeping induction for a continuous 
hypoxic conditions (Appelhoff, et al., 2004). In addition, PHD-3 assures the elimination 
of excessive HIF-α after re-oxygenation (Fong and Takeda, 2008). Figure 1.4(a) shows 
the sequence alignment of PHD1-3. 
Up to this date, PHD-2 is the only isoform that it’s structure has been solved in 
crystallographic studies among PHDs. Figure 1.4 (b) shows the crystal structure of PHD-
2 in complex with 8-iodo bicyclic isoquinoline, revealing it is made up of eight major 
antiparallel β-strands (also known as double stranded β helix, DSBH), three conserved 
α-helices (α-1, α-2, α-3) and other minor β-sheets pack along the DSBH core. Another 
C-terminal α-helix (α-4) stretches from the β-10. On top of that, cofactor ferrous ion 
(Fe2+) was buried deeply in the active site pocket, coordinated by a set of ligands (His313, 
Asp315, His374) in tridentate manner forming the Fe2+/2-OG complexes (Mcdonough 
et al., 2006). Upon binding of PHD-2 to the HIF-1α, the hydroxylation site and the 
complexes are separated due to the CODD HIF-1α structural changes (Chowdhury et al., 















Figure 1.4: (a) Sequence alignment of Human PHD-1, PHD-2 and PHD-3. Residues 
shaded with black were highly conserved sequence similarities (Flashman et al., 2008). 
(b) Ribbon presentation of crystallographic PHD-2 (cyan and violet) in complex with 8-
iodo bicyclic isoquinoline (yellow) and iron (pink). The eight major β-strands of DSBH 
are highlighted in violet and numbered (βI-βVIII) and α-helices in cyan (α1-α4). (Figure 










1.5  PHD Inhibitors 
 
Different classes of prolyl hydroxylase domains 2 (PHD-2) inhibitors have been 
developed and reported in recent years, arises from their isoforms abundancy and crucial 
role in regulating HIF-α subunits.  
 
1.5.1  Iron chelator 
The iron chelator desferrrioxamine (DFO) is the first reference compound in 
PHD inhibition related studies, for its role in elevating erythropoietin RNA and HIF-1α 
levels in cells. DFO is a non-competitive inhibitor which chelates and occupies iron 
(Fe2+) in the active site and subsequently deactivate the HIF prolyl hydroxylases. 
However, based on the finding of Hirsilä et al. (2005), DFO did not inhibited crude type 
PHD-2 at all up to 1mM concentration but inhibited about 40-50% of the activity of  





1.5.2  Divalent transition metal ions  
PHDs are inhibited through the competition of divalent transition metal ions such 
as Co2+, Cu2+, Zn2+, Mn2+, Ni2+ or Cd2+ with respect to Fe2+. Among the divalent metal 
ions, Cu2+ shows the most potent inhibitory activity followed by Zn2+, Mn2+, Co2+, Cd2+ 
and lastly Ni2+ (Sekirnik et al. , 2005). The IC50 values of these transition metal ions 





Table 1.1: The IC50 values of various divalent transition metal ions against PHD-2 
(Sekirnik et al. , 2005). 
 IC50 (μM) 
Zn2+ Mn2+ Co2+ Ni2+ Cu2+ Cd2+ 
PHD-2 9.3 21 48.3 185.2 6.6 57.4 
 
1.5.3  2-OG competitive PHD inhibitors 
On top of that, 2-OG competition is another mechanism use to inhibit PHDs. 
Most of the reported inhibitors compete with 2-OG or probably oxygen and chelate to 
the active site metal ion in bidentate fashion. In 1995, Baader et al., found that N-
oxalyglycine (NOG) is a potent PHD inhibitor and its binding mode is through 2-OG 
competition. The carboxylate and amide oxygen of NOG chelate to the manganese ion 
(Mn2+), substituting ferrous ion (Fe2+) in bidentate manner (Epstein et al., 2001) in the 
PHD2-NOG complex crystallographic study.   
Others reported 2-OG mimic inhibitors such as 2,4-pyridinedicarboxylate (2,4-
PDCA), 3-hydroxypyridine-2-carbonyl-glycine, 2-(3-hydroxypicolinamido)acetic acid 
and N-((3-hydroxy-6-chloroquinolin-2-yl)carbonyl)glycine showed satisfactory 
inhibitory activity against PHD-2 (Table 1.2). However, NOG and 2,4-PDCA have been 
reported as non-selective PHDs inhibitor as these simple 2-OG mimic inhibitors also 
inhibited wide range of 2-OG oxygenases (Chowdhury et al., 2013).  
In 2003, FibroGen, InC. reported that 1-chloro-4-hydroxyisoquinoline 
glycinamidec or bicyclic isoquinoline (BIQ) as a PHD-2 inhibitor and declared it as their 
first clinical candidate in 2008, named as FG-2216 and FG-4592 as backup candidate 
(Thevis et al., 2008). Another derivative compound of BIQ: L-Ala BIQ showed less 
potent inhibitory activity as compared to BIQ. Furthermore, a series of 4-hydroxy-2-
oxo-1,2-dihydroquinoline derivative (4HQs) were reported as selective PHD-2 





On top of that, Barrett et al., 2011 characterized a pharmacological compound  
1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2yl)-1H-pyrazole-4-carboxylic 
acid (JNJ-42041935) as potent and selective PHD-2 inhibitor. Deng et al., (2013) also 
discovered 2,8-Diazaspiro [4.5] decan-1-ones as potent, orally bioavailable PHD2 
inhibitors. The reported IC50 value for the PHD-2 inhibitors are summarized in Table 
1.2. The discrepancies in the reported IC50 values reflected the variations especially 
assay conditions in the respective experiments.   
 
Table 1.2: The reported IC50 values of 2-OG competitive inhibitors against PHD-2 
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2, 8-Diazaspiro [4.5] decan-1-ones 
1.3h 
The IC50 value
a, valueb, valuec, valued, valuee , valuef, valueg, valueh and valuei were 
reported by Hirsilä et al., (2005); King et al., (2010); Chowdhurry et al., (2011); 
Warshakoon et al., (2006); Chowdhurry et al., (2013);  Lei et al., (2015); Barrett et al., 
2011; Deng et al., (2013) respectively. 
              
 
 
1.5.4 Dual-action PHD inhibitors 
Yeoh et al., (2013) reported a diacylhydrazine-based dual-action inhibitors that 
induce the binding of second iron (Fe2+) in the PHD-2 active site. Five compounds were 
identified as potent (<10 μM) among the diacylhydrazine inhibitors. The reported IC50 







Table 1.3: The IC50 of values of diacylhydrazine-based dual-action PHD inhibitors in 
PHD-2  active site (Yeoh et al., 2013) 
 























1.6 Therapeutic uses of PHD inhibitors 
Utilization of PHD inhibitors to upregulate HIF level is one of the therapeutic 
indications for ischemic diseases. As mentioned by Soni (2014), small molecule based 
PHD-2 inhibitors would be a better alternative in treating renal anemia. To date, the roles 
of PHD-2 inhibitors are proven as an intensive strategy against renal anemia, ischemia 
and inflammatory diseases (Maxwell and Eckardt. 2016; Gupta and Wish, 2017; 
Sugahara et al., 2017).  
Bernhardt et al., 2006 reported the effect of PHD inhibitor as pharmacological 
“ischemic preconditioning” agent in activating HIF prior to the right nephrectomy 
surgery in rat significantly reduces tissue injury and apoptosis. Eckle et al., (2008) also 
reported the usage of PHD inhibitors before the ischemic/reperfusion (I/R) injury 
provides strong protection to cardiac tissue and minimizes the extent of myocardial 
infarct. Furthermore, a study reported by Elena et al., (2011) mentioned that PHD 
inhibitors also play a crucial role in lowering the ischemic infarct volume and ameliorate 
ischemic brain injury due to cerebral ischemia. In addition, patients that suffered from 
severe infectious or ischemic diseases would face one of the persistent complications 
which is lactic acidosis. A study reported by Suhara et al., (2015) suggested that PHD-
2 inhibitors could potentially boost the uptake of lactate for gluconeogenesis and thus 
resolve the life-threatening lactic acidosis condition. The excessive amounts of lactate 
release into the circulation is a result of the anaerobic glycolysis, which is the most 
effective way of produce energy when body cells and tissues are in the demand of 
oxygen.   
PHD inhibitors are also used for the treatment of anemia in patients with chronic 
kidney disease (CKD). Renal anemia arises from the complication of CKD. When an 
impaired kidney fails to produce sufficient erythropoietin (EPO), it directly affects the 





the body. PHD inhibitors have been reported to stimulate erythropoiesis by triggering 
hypoxic response, stabilizing HIF complex and subsequently activates genes encoding 
EPO, EPO receptor, transferrin, transferrin receptor, divalent metal transporter 1 (DMT1) 
copper-carrying protein (ceruloplasmin), and duodenal cytochrome B (Dcytb) (Gupta 
and Wish, 2017; Provenzano et al., 2016).  
Other than that, PHD inhibitors used to elevate HIF levels also found to be a 
potential treatment for chronic wound healing, especially in elderly or diabetic patients 
who have reduced capability in HIF expression. In the wound healing process, HIF-1 is 
crucial in regulating inflammatory and angiogenic responses through the upregulation 
of HIF-driven transcription gene such as vascular endothelial growth factor (VEGF), 
nitric oxide synthases, adrenomedullin, metabolic proteins (GLUT-1), soluble growth 
factors (TGF-β and VEGF) and ECM components (collagen and fibronectin) (Hong et 
al., 2015; Thangarajah et al., 2009). 
 
1.7  Amide bond and PHD inhibitors 
Amide bond formation is well-known as one of the important reactions in 
organic chemistry. There are three known types of amide: carboxamide, sulfonamide 
and phosphoramide. It is a reaction to be reckoned in the phrmaceutical industry due to 
its high polarity, stability and conformational variety properties in  biologically active 










Figure 1.5: Three known types of amide. (a) carboxamide, (b) sulfonamide, (c) 
phosphoramide. 
 
Most of the PHD-2 inhibitors reported consist of carboxamide and sulfonamide  
which have been identidified as one of the crucial functional group contributed to the 
PHD-2 inhibition. There are many reported methods in generating amide compounds 
with the presence of catalyst, additives, coupling reagents, organic solvents, acids or 
bases depends on the substrates used in the reaction scheme.  
One of the reaction schemes reported by Omuaru in 1998 in generating 
carboxamide through the reaction of cyclic anhydrides with aromatic primary amines in 
the presence of benzene under reflux condition as shown in scheme 1.1. 
Scheme 1.1: Reaction of cyclic anhydrides with aromatic primary amines. 
 
 
The amide reaction scheme was further studied by Naik and colleagues (2004) 
in which the amines were reacted with cyclic and acylic anhydride in aqueous media in 
the presence of sodium dodecyl sulfate (SDS), without acid or base reagents, as shown 
in Scheme 1.2.    






Scheme 1.2: Reaction of cyclic and acylic anhydrides with amine in aqueous medium. 
 
1.8  Computer Aided Drug Design (CADD) 
Herbal remedies were recorded in ancient history, as the only resource for all 
kinds of medical treatment purposes due to the limitation of synthetic drugs. The 
emergence of first semi synthetic or synthetic drugs was in the last century with 
unpromising safety and potency features (Lourenco et al., 2012). Researchers from all 
over the world spent an outrageous amount and seemingly endless years on discovering 
a new drug. Every single successfully discovered drug brought to the market could cost 
up to USD$800 million to USD$1.8 billion (Paul et al. 2010). Computer Aided Drug 
Design (CADD) could play an important role in drug discovery field especially in 
pharmaceutical and biochemistry research. CADD could reduce the overall costing, 
speeding up the time of bringing lead candidates to market and provide better insight 





CADD consists of two major techniques: ligand-based drug design (LBDD) and 
structure-based drug design (SBDD). The differences between the two techniques are 
the formal one is under the condition where the protein structure is unknown while the 
later one is when the three-dimensional structure of target protein is available which can 
be download at the Protein Data Bank website: www.pdb.com. LBDD utilizes the 
diverse biological activities information of a series of reported active molecules, 
overlapping the common features such as hydrophobic, stearic or hydrophillic group 
against the biological targets of interest and hence building up the pharmacophore model 
(Huang et al., 2010). SBDD utilizes the 3D structure of reported protein as well as the 
receptor in order to begin the design of potential compounds (Scapin, 2006). The overall 



























































Figure 1.6: The progress of discovering drug candidates using CADD. (Figure adapted 






Structure of target protein 
Structure-based drug design Ligand-based drug design 
- Ligand docking 
- De novo design 
- Molecular dynamic 
- Pharmacophore 
modelling 





- Ligand based virtual 
screening 






1.9 Problem Statement 
Cardiovascular diseases (ischaemic heart disease and stroke) remained on top of 
the chart as the global diseases over the years, take up the largest percentage of deaths, 
estimated of 17.5 million (World Health Organization, 2009). Both of these diseases 
arise from the narrowing of coronary heart arteries due to the formation of fatty deposits 
(atheroma) and blood clot (thrombosis) in the artery wall, which could partially 
restricted or totally blocked the flow of oxygenated blood to heart muscle and brain 
(Davies and Hollman, 2002). These subsequently lead to tissue hypoxia. Without proper 
and immediate action taken, heart may become permanent damaged and brain cells die 
within minutes. (Hachinkski et al., 2006; Kent et al., 2011). However, when human body 
facing self-regulation failure in upregulate HIF for adaptive responses, proly 
hydroxylase domain (PHD) inhibitors play a crucial role in activate the HIF 
transcriptional activity artificially which have been proven as one of the therapeutic 
indication for ischemic heart disease and cerebral ischemia (Maxwell and Eckardt. 2016; 
Gupta and Wish, 2017; Sugahara et al. 2017).  According to a review done by Yan et 
al., (2010), most of the PHD inhibitors consisted of two essential functional groups: 
amide and carboxylic group. Roxadustat (FG4592), Vadadustat (AKB-6548) and 
Daprodustat (GSK-1278863) that currently undergoing clinical investigation consist of 
these functional groups. On top of that, Yeoh et al., (2013) also reported that a 
functionalized bicylic PHD inhibitors show better inhibitory potency than monocylic 
ring.  
In this study, a series of 4-oxobutanoic acid analogues that fullfiled the above 
criterias were tested as potential PHDs inhibitors as well. These compounds were 
synthesized through the reaction between commercially available amine and succinic 





1.10  Research Objectives 
 The research objectives: 
1. To design a series of 4-oxobutanoic acid analogues as potential PHD-2 inhibitor using 
computer aided technique (molecular docking).  
2. To synthesize and characterize the synthesized 4-oxobutanoic acid analogues using 
various spectroscopic methods.  
3. To study the inhibitory potencies of 4-oxobutanoic acid analogues. 
 
Scope of study: 
This research focuses on the design, synthesis and characterization of 4-
oxobutanoic acid analogues as potential HIF prolyl hydroxylase domain-2 (PHD-2) 
inhibitors. The compounds were designed based on the PHDs inhibitors as reported in 
literature review. In sillico computational and molecular docking studies were employed 
as the following step, guided by Dr Muhd Yusuf from School of Pharmaceutical 
Sciences to screen over the designed compounds based on their fulfilment of Lipinski’s 
parameter, free energy of binding and binding pose in the active site pocket of PHD-2 
crystallographic structure which can be downloaded at www.pdb.com. Compounds 
which gave positive results in docking studies were further synthesized and 
characterized using various spectroscopic techniques such as NMR (1D and 2D), mass 
spectrometry, CHN elemental analysis and FTIR. The inhibitory potencies of 4-
Oxobutanoic acid analogue compounds were screened using PHD-2 RapidFire assay 









 CHAPTER 2  
  
MATERIALS AND METHODS 
 
2.1  Chemicals and Solvents  
All of the commercial chemicals and reagents that involved in the synthesis were 
purchased from Sigma-Aldrich, Acros Organics, Fisher Scientific and Maybridge 
Chemical without further purification. The solvents used: hexane, dichloromethane, 
ethyl acetate, methanol, tetrahydrofuran, chloroform, anhydrous ethanol and 
dimethylformamide were all analytical grade from QRëC.  
 
2.2  General Experimental Procedures 
2.2.1.  Reaction Monitoring 
All the reactions were monitored by using the aluminium supported silica gel 
60F254 thin layer chromatography (TLC) plate (Merck 1.05554.0001). The starting 
material, reacting reagent, reaction mixture and catalyst (if used) were spotted on the 
TLC plate, eluted with solvent system of dichloromethane (DCM) and methanol (MeOH) 
with different ratio. TLC was conducted in a closed glass tank saturated with the vapor 
of eluent. The spots on the developed TLC plate were then visualized by CAMAG® 









2.2.2  Isolation and Purification  
2.2.2(a) Column Chromatography  
Silica gel 60F, 230-400 mesh ASTM (Merck 1.09385.1000) was used for column 
chromatography as stationary phase and different organic solvents were used as mobile 
phase. The silica was first mixed with hexane and formed concoction before it was 
packed into column. Hexane was loaded continuously in the column for at least one hour 
before putting samples into the column.  
The sample was dry-loaded into the column consisting silica gel and eluted with 
increasing proportions hexane, DCM as well as MeOH which then formed different 
fractions of solvent system. The sequence of solvent system eluted in the column 
chromatography followed the increase in polarity of the chemical solvents. The collected 
eluent fractions were dried under rotary evaporator and monitor with TLC analysis. 
Separated components with the same retention factor (Rf) were combined in the same 
vial.  
2.2.2(b) Recrystallization 
A single solvent recrystallization was employed for the purification of reaction 
product. The targeted compound and impurities were completely dissolved in the desired 
hot solvent. Then the solution slowly cooled to room temperature and allowed to stand 
for the crystals to grow. The crystals obtained were then filtered by suction filtration. 
The resulting crystals were then dried in the aspirator.      
 
2.2.3.  Characterization of Compounds 
All of the synthesized compounds were sent for melting point determination as 





Magnetic Resonance (1D and 2D), Fourier Transform Infrared Spectroscopic (FT-IR), 
mass spectrometry (MS) and elemental analysis.  
2.2.3(a) Nuclear Magnetic Resonance Spectroscopy (NMR) 
The Nuclear Magnetic Resonance (NMR) spectra of the synthesized compounds 
were recorded on Bruker Avance spectrometers; 500 MHz for 1H NMR and 125 MHz 
for 13C NMR. The 2D spectra included Correlated Spectroscopy (COSY), Heteronuclear 
Single Quantum Correlation (HSQC) and Heteronuclear Multiple Bond Correlation 
(HMBC) for the compounds were also recorded on Bruker Avance 500 spectrometer at 
500 MHz. Deuterated dimethylsulfoxide (DMSO-d6) was used to dissolved the samples 
with tetramethylsilane (TMS) as the internal standard. Chemical shifts (δ) were recorded 
in part per million (ppm) and coupling constant (J) in Hz.    
2.2.3(b) Fourier Transform Infrared Spectroscopy (FT-IR) 
All of the synthesized compounds were characterized by Perkin-Elmer 2000 FT-
IR spectrometer. A small amount of synthesized compound were grounded into powder 
form with dry potassium bromide (KBr) in mortar at 1:10 ratio. The mixture powder was 
then compressed into a thin transparent pellet for the FTIR analysis in the range of 4000 
to 400 cm-1.  
2.2.3(c) Elemental Analysis 
All of the synthesized compounds were analyzed by Perkin Elmer series II, 2400 
CHN analyzer by the Science officer of School of Chemical Science, USM.  
2.2.3(d) Direct Infusion Mass Spectrometry (DIMS) 
All of the synthesized compounds were analyzed by TSQ Quantum TM Access 
MAX Triple Quadrupole Mass Spectrometer. Samples dissolved in 50/50 
